Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, C. M.
NEUROLOGY 1981;31:1569
© 1981 American Academy of Neurology

Visual disturbances associated with quinidine and quinine

C. M. Fisher, M.D.

Neurology Service of the Massachusetts General Hospital and the Department of Neurology Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Fisher, Harvard Medical School, Massachusetts General Hospital, Department of Neurology. Fruit Street, Boston. MA 02114.

Obscurations of vision were experienced by three patients taking quinidine and by two patients taking quinine. In four, transient symptoms developed on exposure to light after first awaking in the morning, and in the fifth, there was persistent photophobia. In two patients, there was a large central scotoma, in one, swirling dark clouds, and in the fourth, flickering of vision. The duration was 1 to 4 minutes in three patients and 45 to 60 minutes in one patient. The symptoms, which are benign, may be confused with the prodromal visual manifestations of thrombotic cerebrovascular disease.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.